My Work in Prostate Cancer Research: From Robotic Surgery to Better Patient Outcomes

How do we treat the cancer properly while preserving the man's quality of life?

That question has shaped everything I do, clinically and academically. It sits behind every operation, every clinic conversation and every piece of research I am involved in.

My main clinical focus is prostate cancer: robot assisted radical prostatectomy, transperineal prostate biopsy and decision-making for men with newly diagnosed or suspected disease. Alongside this, I work on robotic surgery outcomes, nerve sparing techniques, counselling regarding focal therapy, active surveillance, continence recovery, imaging-led treatment planning, digital pathology and the evolutionary biology of cancer.

Robotic prostate cancer surgery

Robot assisted radical prostatectomy is now one of the main surgical treatments for localised prostate cancer. The operation is technically demanding because it has to balance several priorities at once: complete cancer removal, protection of urinary control, preservation of erectile function where safe, and accurate reconstruction.

My research and clinical practice have both focused on these trade-offs. I am particularly interested in how surgical technique, patient selection and detailed preoperative planning can improve functional outcomes without compromising cancer control.

This includes work on nerve sparing robotic prostatectomy. The nerves responsible for erections run very close to the prostate. In some men they can be preserved safely. In others, the cancer position or stage means a wider excision is needed. The skill lies in knowing when nerve sparing is appropriate, when it carries risk, and how to tailor the operation to the individual patient.

I have contributed to published work reviewing nerve sparing techniques in robotic prostatectomy, covering anatomy, operative strategies and functional outcomes.

High-risk and complex prostate cancer

Not all prostate cancers behave the same way. Some are low risk and suitable for careful monitoring. Others are more aggressive and require active treatment.

I have focused particularly on the management of more complex prostate cancer, including cases where disease is higher risk or where previous treatment has failed.

One area of published work involves salvage robot assisted radical prostatectomy: surgery performed after previous treatment, such as radiotherapy or focal therapy, when cancer has recurred locally. These operations are more difficult because tissues may be scarred, planes are less clear and complication risks are higher.

Men diagnosed with prostate cancer deserve proper options if their cancer returns. Treatment is not just about the first decision.

Focal therapy and active surveillance

Focal therapy aims to treat only the cancerous part of the prostate rather than the whole gland. In carefully selected men, this may reduce side effects compared with radical treatment. The evidence has to be examined carefully, because undertreating significant cancer carries real risk.

I contributed to work examining focal ablative therapy for localised prostate cancer, assessing how prostate-targeted treatment compares with standard approaches and helping clarify the strengths and limitations of the evidence base.

Active surveillance is equally important. Some prostate cancers are unlikely to cause harm in the short or medium term. For these men, immediate surgery or radiotherapy may produce side effects without clear benefit.

Good surveillance requires proper risk assessment, MRI, PSA monitoring, biopsy information and honest discussion with the patient. The challenge is not simply deciding who can avoid treatment today. It is identifying who can avoid treatment safely over the longer term.

Evolutionary biology and prostate cancer

Prostate cancer is not a single uniform disease. Some tumours remain quiet for years. Others behave aggressively from an early stage. Understanding why this happens means looking beyond the tumour in isolation.

Ageing, hormones, inflammation, metabolism, immune function and the local environment within the prostate may all influence how cancer emerges and progresses.

Cancer can be understood as a process of adaptation and selection. Cells acquire changes, respond to pressure, compete with surrounding tissue and sometimes develop resistance to treatment. Treatments such as surgery, radiotherapy and hormone therapy do not act on a static disease. They apply selective pressure. Some cancer cells are destroyed; others may survive, adapt or recur.

For men I see in clinic, this thinking shapes how I assess whether a cancer is likely to stay quiet or change over time. It informs decisions about treatment timing, treatment intensity and long-term monitoring. It is one reason why careful tissue collection and thorough long-term follow-up matter so much.

Imaging-led prostate cancer care

Modern prostate cancer care depends on high-quality imaging.

MRI has changed how we diagnose prostate cancer, target biopsies and plan treatment. It gives important information about tumour location, size, proximity to the capsule, relationship to the nerves and possible spread beyond the prostate.

My current work moves further into this area: using imaging, pathology and outcomes data together to improve treatment planning.

One project I am developing correlates preoperative prostate MRI with whole mount prostatectomy histology. The aim is to compare what the MRI shows before surgery with what the removed prostate reveals under the microscope. Done properly, this work improves how we predict tumour extent, grade, margin risk and suitability for nerve sparing surgery.

In plain terms, the aim is to make the preoperative map more accurate. If we can better understand the relationship between MRI appearances and true pathology, surgery can be planned more precisely, patients can be counselled more accurately, and both cancer control and functional recovery improve.

Detailed MRI analysis and tumour mapping

A developing area of my research involves voxelomics: the analysis of MRI data at the most granular level available.

A voxel is the three-dimensional equivalent of a pixel. Each voxel in a prostate MRI contains information about the tissue in that small region of the gland. By linking this imaging data to whole mount pathology, it becomes possible to create far more detailed maps of prostate cancer behaviour, matching MRI features to actual tumour grade, location, margin risk and extent of disease.

The aim is not to produce more complex imaging for its own sake. The aim is to make imaging more useful for individual patients.

If MRI can be linked more accurately to pathology, it can help answer practical surgical questions: whether a tumour is truly confined to the prostate, whether nerve sparing is safe on a given side, where the highest-risk region of the gland lies, and whether a man needs treatment or can be safely monitored.

This is early work, but the principle is important. Scans should not only be looked at. They should be measured, tested against pathology and used to improve decisions.

Biobanking and the importance of tissue

When a man has a prostate biopsy or prostatectomy, the tissue removed contains a large amount of biological information. Some of that information is used immediately for diagnosis: cancer grade, tumour volume, margin status and stage.

Tissue can also be stored carefully, with appropriate consent, so that future research can ask better questions.

A good prostate cancer biobank links tissue samples with clinical data, imaging, pathology, treatment details and long-term outcomes. That combination is powerful. It allows researchers to study why some cancers progress, why some recur, why some respond to treatment and why others become resistant.

For my own work, biobanking connects directly with MRI histology correlation and detailed image analysis. If preoperative MRI, whole mount histology, digital pathology, genomic information and follow-up outcomes can be linked properly, a much more detailed picture of individual prostate cancer behaviour becomes possible.

The aim is not to collect tissue for the sake of it. The aim is to create a resource that moves prostate cancer care away from broad categories and towards precise, individualised treatment.

Tissue collected from patients today may answer the clinical questions that matter most tomorrow.

Data, outcomes and honest measurement

Outcomes should be measured properly.

In prostate cancer surgery, it is not enough to say that an operation went well. The details matter: margin status, PSA response, continence recovery, erectile function, complications and longer-term follow-up.

Patients deserve realistic information. That means collecting data, reviewing it honestly and using it to improve practice.

My clinical work is closely linked to outcomes tracking, covering operative complexity, cancer clearance, continence recovery, sexual function and postoperative PSA monitoring. Better data leads to better decisions.

Current clinical and research interests

Robotic radical prostatectomy. Improving surgical planning, nerve sparing decisions, margin control and functional recovery.

Modified and Retzius sparing approaches. Exploring surgical techniques that may improve early continence recovery in selected patients.

MRI and pathology correlation. Using whole mount prostatectomy specimens to better understand how MRI findings relate to true tumour position, grade and extent.

Detailed MRI analysis and tumour mapping. Developing ways to link MRI data, histology and clinical outcomes at a more precise spatial level.

Biobanking. Supporting tissue collection linked to imaging, pathology and follow-up data, so that future research can ask better biological and clinical questions.

Evolutionary biology of prostate cancer. Exploring how ageing, hormones, metabolism, immune function and treatment pressure shape tumour behaviour over time.

Risk prediction before surgery. Improving how we identify extracapsular extension, margin risk and suitability for nerve preservation.

Outcomes after treatment. Tracking continence, erectile function, PSA response and patient recovery after surgery.

Patient information and support. Developing clearer pathways so men understand their diagnosis, treatment choices and recovery.

Why this research matters to patients

Research can sound remote from everyday clinical care, but in prostate cancer it is intensely practical.

It affects the advice a man receives in clinic. It affects whether he is offered surveillance, surgery, radiotherapy or another treatment. It affects whether nerve sparing is attempted. It affects how accurately he is counselled about continence and sexual function. It affects how closely he is followed after treatment. It affects whether he feels properly informed rather than pushed through a system.

My aim is to bring together surgical experience, imaging, pathology, tissue biology and outcomes data to make prostate cancer treatment more precise, more honest and more individualised.

Prostate cancer care should not be based on guesswork or habit. It should be based on careful assessment, technical skill, good data and clear communication.

Final thought

The future of prostate cancer care is not just better technology. It is better judgement.

MRI, robotics, pathology, genomics, biobanking and outcomes data all matter, but only if they help make better decisions for individual patients.

That is where my work is focused: treating the cancer properly while helping men recover their confidence, function and quality of life.